866-997-4948(US-Canada Toll Free)

Hematology Partnering Terms and Agreements

Published By :

Current Partnering

Published Date : Jul 2013

Category :

Hematology

No. of Pages : 630 Pages


The Hematology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the hematology partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in hematology partnering deals
  • Average deal terms for headline, upfront and royalty by stage of development
  • Hematology partnering agreement structure
  • Hematology partnering contract documents
  • Top hematology deals by value
  • Most active hematology dealmakers

The Hematology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the hematology partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter hematology partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors infectives technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases do not.

This report contains over 1,000 links to online copies of actual hematology deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.

The initial chapters of this report provide an orientation of hematology dealmaking and business activities. 

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in hematology dealmaking since 2007 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading hematology deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top bigpharma companies with a brief summary followed by a comprehensive listing of hematology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all hematology deals since 2007 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all hematology partnering deals signed and announced since 2007. The chapter is organized by specific hematology therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all hematology partnering deals signed and announced since 2007. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in hematology partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of hematology technologies and products.

Report scope

Hematology Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to hematology trends and structure of deals entered into by leading companies worldwide.

Hematology Partnering Terms and Agreements includes:

  • Trends in hematology dealmaking in the biopharma industry since 2007
  • Analysis of hematology deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of hematology deal contract documents
  • Comprehensive access to over 1,000 hematology deal records
  • The leading hematology deals by value since 2007
  • Most active hematology dealmakers since 2007

In Hematology Partnering Terms and Agreements, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Hematology Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,000 hematology deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise hematology rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?
Table of Content

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in hematology dealmaking
2.1. Introduction
2.2. Hematology partnering over the years
2.3. Bigpharma hematology dealmaking activity
2.4. Bigpharma not active in hematology
2.5. Hematology partnering by deal type
2.6. Hematology partnering by industry sector
2.7. Hematology partnering by stage of development
2.8. Hematology partnering by technology type
2.9. Hematology partnering by hematology indication
2.10. Average deal terms for hematology 
2.10.1 Hematology headline values
2.10.2 Hematology upfront payments 
2.10.3 Hematology milestone payments 
2.10.4 Hematology royalty rates

Chapter 3 Leading hematology deals
3.1. Introduction
3.2. Top hematology deals by value
3.3. Top hematology deals involving bigpharma

Chapter 4 Bigpharma hematology deals
4.1. Introduction
4.2. How to use bigpharma partnering deals
4.3. Bigpharma hematology partnering company profiles
Amgen
Astellas
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Bristol-Myers Squibb 
Celgene 
CSL 
Daiichi Sankyo 
Eisai
Eli Lilly 
GlaxoSmithKline 
Grifols 
Hospira 
Johnson & Johnson
Janssen Biotech 
Lundbeck 
Menarini 
Merck & Co 
Novartis 
Novo Nordisk 
Pfizer 
Purdue 
Roche 
Sanofi 
Shire 
Takeda 
Teva 
Watson

Chapter 5 Hematology partnering contracts directory
5.1. Introduction 
5.2. By deal type 
Asset purchase 
Assignment 
Bigpharma outlicensing 
Co-development 
Collaborative R&D 
Contract service 
Co-promotion 
Cross-licensing 
Development 
Distribution 
Equity purchase 
Evaluation 
Licensing 
Litigation 
Manufacturing 
Marketing 
Material transfer
Option 
Research 
Settlement 
Sub-license 
Supply 
Technology transfer 
Termination 
5.3. By stage of development 
Discovery 
Formulation 
Marketed 
Phase I 
Phase II 
Phase III 
Preclinical 
Regulatory 
5.4. By technology type 
Analysis 
Assays 
Biological compounds
Biomaterials 
Blood products 
Cell therapy 
Clinical testing 
Devices 
Diagnostics 
Discovery tools 
Drug delivery 
Enabling technology 
Equipment 
Facilities 
Genomics 
Industrial chemicals 
Nanotechnology 
Oligonucleotide 
Orphan drug 
Packaging 
Peptides 
Processes 
Proteomics 
Radio/Chemo-therapy
Recombinant DNA 
Regenerative medicine 
Research services 
Research supplies 
RNA therapeutics
Screening 
Small molecules 
Software tools 
Stem cells

Chapter 6 Hematology dealmaking by indication
6.1. Introduction 
6.2. Deals by therapeutic indication 
Hematology 
Anemia 
Iron deficiency 
Blood substitute 
Neutropenia 
Polycythemia 
Thalassemia 
Thrombocytopenia 
Vitamin K Deficiency 
Von-Willebrand disease 

Chapter 7 Partnering resource center
7.1. Online partnering 
7.2. Partnering events 
7.3. Further reading on dealmaking 

Appendices 

Appendix 1 Directory of hematology deals by company A-Z 2007-2013

Appendix 2 Directory of hematology deals by deal type 2007-2013

Appendix 3 Directory of hematology deals by stage of development 2007-2013

Appendix 4 Directory of hematology deals by technology type 2007-2013

Appendix 5 Deal type definitions 
About Wildwood Ventures 
Current Partnering 
Current Agreements 
Recent titles from CurrentPartnering
Order Form Reports

List of Chart


Figure 1: Hematology partnering since 2007 
Figure 2: Bigpharma top 50 hematology deals 2007 to 2012
Figure 3: Bigpharma hematology deal frequency 2007 to 2012
Figure 4: Inactive bigpharma in hematology 2007-2013 
Figure 5: Hematology partnering by deal type since 2007 
Figure 6: Hematology partnering by industry sector since 2007
Figure 7: Hematology partnering by stage of development since 2007
Figure 8: Hematology partnering by technology type since 2007 
Figure 9: Hematology partnering by hematology target since 2007 
Figure 10: Hematology deals with a headline value 
Figure 11: Hematology deal headline value distribution, US$million discovery stage
Figure 12: Hematology deal headline value distribution, US$million preclinical stage
Figure 13: Hematology deal headline value distribution, US$million phase I stage
Figure 14: Hematology deal headline value distribution, US$million phase II stage
Figure 15: Hematology deal headline value distribution, US$million phase III stage
Figure 16: Hematology deal headline value distribution, US$million regulatory stage 
Figure 17: Hematology deal headline value distribution, US$million marketed stage 
Figure 18: Summary median headline value by stage of development, 2007-2013
Figure 19: Hematology deals with upfront payment values
Figure 20: Hematology deal upfront payment distribution, US$million discovery stage 
Figure 21: Hematology deal upfront payment distribution, US$million preclinical stage 
Figure 22: Hematology deal upfront payment distribution, US$million phase I stage 
Figure 23: Hematology deal upfront payment distribution, US$million phase II stage 
Figure 24: Hematology deal upfront payment distribution, US$million phase III stage 
Figure 25: Hematology deal upfront payment distribution, US$million regulatory stage 
Figure 26: Hematology deal upfront payment distribution, US$million marketed stage 
Figure 27: Summary median upfront payments by stage of development, 2007-2013 
Figure 28: Hematology deals with milestone payments
Figure 29: Hematology deal milestone distribution, US$million discovery stage
Figure 30: Hematology deal milestone distribution, US$million preclinical stage
Figure 31: Hematology deal milestone distribution, US$million phase I stage 
Figure 32: Hematology deal milestone distribution, US$million phase II stage 
Figure 33: Hematology deal milestone distribution, US$million phase III stage 
Figure 34: Hematology deal milestone distribution, US$million regulatory stage
Figure 35: Hematology deal milestone distribution, US$million marketed stage
Figure 36: Hematology deals with royalty rates, %
Figure 37: Hematology deal royalty rate distribution, US$million discovery stage
Figure 38: Hematology deal royalty rate distribution, US$million preclinical stage
Figure 39: Hematology deal royalty rate distribution, US$million phase I stage
Figure 40: Hematology deal royalty rate distribution, US$million phase II stage
Figure 41: Hematology deal royalty rate distribution, US$million phase III stage
Figure 42: Hematology deal royalty rate distribution, US$million regulatory stage
Figure 44: Summary median royalty rate by stage of development, 2007-2013
Figure 45: Top hematology deals by value since 2007
Figure 46: Top hematology deals signed by bigpharma value since 2007
Figure 47: Online partnering resources 
Figure 48: Forthcoming partnering events

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *